The treatment of mesothelioma has seen a revolution in recent years, with the introduction of cytoreductive surgery (CRS) combined with heated intraoperative intrapleural chemotherapy (HIPEC). This innovative approach has been shown to provide better outcomes for patients with this aggressive and difficult-to-treat cancer. In this article, we will explore the potential benefits and risks associated with this cutting-edge treatment, as well as its potential applications in other forms of cancer. CRS with HIPEC is a complex procedure that requires a specialized skill set from both the oncologist and surgeon. This article will provide an overview of the procedure and its advantages and disadvantages, as well as discussing how it is being used to treat mesothelioma.
We will also explore the research being done to further develop and refine CRS with HIPEC for more widespread use. Cytoreductive surgery (CRS) with heated intraoperative intrapleural chemotherapy (HIPEC) is an effective treatment for malignant mesothelioma that comes with both potential benefits and risks. Patients should consult their doctor for more information about the procedure, including pre- and post-operative care. In conclusion, CRS and HIPEC are becoming increasingly popular treatments for mesothelioma, offering patients a viable treatment option.